Study wrapper · #604
Growth hormone secretagogues prevent dysregulation of skeletal muscle calcium homeostasis in a rat model of cisplatin-induced cachexia.
Editor's note
In a rat model of cisplatin-induced cachexia, researchers reported that chemotherapy disrupted skeletal-muscle calcium homeostasis, roughly doubling resting intracellular calcium and reducing calcium transients alongside muscle atrophy and weakness. Two growth hormone secretagogues, hexarelin and JMV2894, markedly reduced these calcium abnormalities and were associated with preserved muscle function on grip-strength and ultrasound measures. The study strengthens the mechanistic case that calcium dysregulation contributes to chemotherapy-related wasting and that GHS can blunt it. It remains a single preclinical model, with hexarelin studied alongside a novel compound. These are preclinical findings; human data are needed before any clinical conclusions can be drawn.
Plain-language abstract
Chemotherapy can cause muscle wasting (cachexia). Researchers studied this in rats given the chemotherapy drug cisplatin and tested two growth-hormone-releasing peptides, hexarelin and an experimental one, JMV2894. Cisplatin threw off the calcium balance inside muscle fibers, roughly doubling resting calcium and weakening calcium signals, while shrinking the muscle and reducing strength. Both peptides largely corrected the calcium problem and helped preserve muscle function, measured by grip strength and ultrasound. The authors conclude that disrupted calcium handling plays a key role in this kind of muscle wasting and that these peptides can counter it. The abstract reports no adverse events. These are preclinical findings in rats; human studies would be needed before any clinical conclusions.